139 related articles for article (PubMed ID: 18358515)
1. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.
Eggener SE; Yossepowitch O; Roehl KA; Loeb S; Yu X; Catalona WJ
Urology; 2008 Jun; 71(6):1016-9. PubMed ID: 18358515
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of prostate-specific antigen velocity in screening for prostate cancer.
Ito K; Yamamoto T; Ohi M; Kubota Y; Fukabori Y; Kurokawa K; Suzuki K; Yamanaka H
Int J Urol; 2002 Jun; 9(6):316-21. PubMed ID: 12110095
[TBL] [Abstract][Full Text] [Related]
5. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
Wolters T; Roobol MJ; Bangma CH; Schröder FH
Eur Urol; 2009 Feb; 55(2):385-92. PubMed ID: 18353529
[TBL] [Abstract][Full Text] [Related]
6. Significance of preoperative PSA velocity in men with low serum PSA and normal DRE.
Makarov DV; Loeb S; Magheli A; Zhao K; Humphreys E; Gonzalgo ML; Partin AW; Han M
World J Urol; 2011 Feb; 29(1):11-4. PubMed ID: 21153643
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time.
Ng MK; Van As N; Thomas K; Woode-Amissah R; Horwich A; Huddart R; Khoo V; Thompson A; Dearnaley D; Parker C
BJU Int; 2009 Apr; 103(7):872-6. PubMed ID: 18990146
[TBL] [Abstract][Full Text] [Related]
8. Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy.
Kryvenko ON; Wang Y; Sadasivan S; Gupta NS; Rogers C; Bobbitt K; Chitale DA; Rundle A; Tang D; Rybicki BA
Prostate; 2019 Jul; 79(10):1090-1098. PubMed ID: 31045267
[TBL] [Abstract][Full Text] [Related]
9. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
[TBL] [Abstract][Full Text] [Related]
10. The role of prostate-specific antigen velocity in prostate cancer early detection.
Potter SR; Carter HB
Curr Urol Rep; 2000 May; 1(1):15-9. PubMed ID: 12084336
[TBL] [Abstract][Full Text] [Related]
11. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.
Fang J; Metter EJ; Landis P; Carter HB
Urology; 2002 Jun; 59(6):889-93; discussion 893-4. PubMed ID: 12031375
[TBL] [Abstract][Full Text] [Related]
12. Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study.
Kitagawa Y; Urata S; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
Anticancer Res; 2015 Sep; 35(9):5031-6. PubMed ID: 26254404
[TBL] [Abstract][Full Text] [Related]
13. Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Kumar A; Godoy G; Taneja SS
Can J Urol; 2009 Jun; 16(3):4655-9. PubMed ID: 19497172
[TBL] [Abstract][Full Text] [Related]
14. Does PSA velocity predict prostate cancer in pre-screened populations?
Schröder FH; Roobol MJ; van der Kwast TH; Kranse R; Bangma CH
Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Mikropoulos C; Selkirk CGH; Saya S; Bancroft E; Vertosick E; Dadaev T; Brendler C; Page E; Dias A; Evans DG; Rothwell J; Maehle L; Axcrona K; Richardson K; Eccles D; Jensen T; Osther PJ; van Asperen CJ; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Hart R; Glover W; Lam J; Taylor L; Salinas M; Feliubadaló L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Cook J; Rosario DJ; Buys SS; Conner T; Domchek S; Powers J; Ausems MG; Teixeira MR; Maia S; Izatt L; Schmutzler R; Rhiem K; Foulkes WD; Boshari T; Davidson R; Ruijs M; Helderman-van den Enden AT; Andrews L; Walker L; Snape K; Henderson A; Jobson I; Lindeman GJ; Liljegren A; Harris M; Adank MA; Kirk J; Taylor A; Susman R; Chen-Shtoyerman R; Pachter N; Spigelman A; Side L; Zgajnar J; Mora J; Brewer C; Gadea N; Brady AF; Gallagher D; van Os T; Donaldson A; Stefansdottir V; Barwell J; James PA; Murphy D; Friedman E; Nicolai N; Greenhalgh L; Obeid E; Murthy V; Copakova L; McGrath J; Teo SH; Strom S; Kast K; Leongamornlert DA; Chamberlain A; Pope J; Newlin AC; Aaronson N; Ardern-Jones A; Bangma C; Castro E; Dearnaley D; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lubinski J; Grindedal EM; McKinley J; Shackleton K; Mitra AV; Moynihan C; Rennert G; Suri M; Tricker K; ; Moss S; Kote-Jarai Z; Vickers A; Lilja H; Helfand BT; Eeles RA
Br J Cancer; 2018 Jan; 118(2):266-276. PubMed ID: 29301143
[TBL] [Abstract][Full Text] [Related]
16. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
[TBL] [Abstract][Full Text] [Related]
17. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
[TBL] [Abstract][Full Text] [Related]
18. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
BJU Int; 2008 Jun; 101(12):1507-12. PubMed ID: 18341627
[TBL] [Abstract][Full Text] [Related]
19. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
Martin NE; Chen MH; Catalona WJ; Loeb S; Roehl KA; D'Amico AV
Cancer; 2008 Aug; 113(4):717-22. PubMed ID: 18615505
[TBL] [Abstract][Full Text] [Related]
20. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.
Loeb S; Roehl KA; Yu X; Han M; Catalona WJ
Urology; 2007 Jan; 69(1):108-12. PubMed ID: 17270629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
